

Efficacy and Safety of Labor Induction by Oral versus Vaginal Misoprostol: A Randomized Controlled Clinical Trial

ABSTRACT

Background: Labor induction is one of the most common practices in obstetrics in developed countries. But, in developing countries, its prevalence is low. This study seeks to compare the efficacy and safety of oral versus vaginal Misoprostol in an area with limited resource.

Patients and Methods: This is a single-blind, randomized controlled clinical trial, conducted at Kisangani, in Democratic Republic of Congo, from September 1, 2022 to February 01, 2023. The study was prospective, had the approval of the ethics committee of Kisangani University, and women signed the informed consent. The sample was 177 patients, of which 89 received oral Misoprostol and 88 for vaginal route. Were included, primiparous and multiparous who controlled their date of last menstruation, and who had a term progressive pregnancy, mono-fetal, in cephalic presentation, fetal heart rate (FHR) within the norms, and had no contraindications of labor induction. Fifty micrograms of Misoprostol were administered either orally or vaginally every six hours. The primary outcomes were the time from drug administrations to uterine contractions, labor time, and vaginal delivery rate. For secondary outcomes, the course of labor as well as the maternal and perinatal prognosis was assessed. The data were encoded on an Excel 2013 sheet and analyzed using EPI INFO and SPSS software.

Results: Labor was induced after 6.18 ± 4.11 h for oral Misoprostol versus 4.03 ± 1.99 h for the vaginal route ($p=0.00$). The duration of labor was 10.85 ± 3.59 h for the oral route, 9.39 ± 2.55 h for the vaginal route. The time from the first dose to delivery was 16.88 ± 6.11 h for the oral route, 13.03 ± 3.32 h for the vaginal route. The delivery rate within 24 hours was 98.9% (87/88) for the vaginal route and 88.8% (79/89) for the oral route ($p=0.00$). The rate of caesarean section was 6.7% for the oral route, 12.5% for the vaginal.

Conclusion: Misoprostol is effective both orally and vaginally. Administered vaginally, it is associated with a reduction in the duration of labor, while it improves maternal and perinatal prognosis.

Keywords: Labor induction; Misoprostol; Efficacy; Safety; Kisangani.

I. INTRODUCTION

Labor induction is an artificial interruption of the course of pregnancy before spontaneous induction with the aim of reducing maternal and perinatal morbidity and mortality (1,2). It is successful when a vaginal birth is obtained within 24 hours and should only be performed if it appears that in terms of health, the mother or the newborn will benefit from a more favorable outcome than if the birth had been later (3).

According to the World Health Organization (WHO) (4), the labor induction rate in developed countries is on average 25%, 11.4% in Latin America and 12.1% in Asia. In Sri Lanka, the labor induction rate is 35.5% (5) and in the United States of America it is 25% (6). In Africa, the rate varies between 1.4-6.8% with an average of 4.9% (7). In Nigeria, a study found a rate of 16.7% in a tertiary hospital in Lagos (8). However, In Eastern Region of DRC, at Kisangani, the rate of labor induction is 3.36% (9).

To induce labor, we use either mechanical technique such as membrane stripping, transcervical placement of a Foley catheter with or without extraamniotic saline infusion, breast stimulation with a breast pump, acupuncture or amniotomy, either drug methods such as oxytocin solution, prostaglandins or intra-amniotic injection of hypertonic saline (10).

However, labor induction may be associated with a risk of failure to induce labor, and like any other intervention, have adverse effects such as hyperkinesia, hypertonia, uterine hyperstimulation, fetal distress, pre-rupture or uterine rupture, cesarean section, postpartum hemorrhage, and in rare cases, fetal or maternal death (11).

WHO recommends the use of oxytocin solution, prostaglandins or amniotomy to induce labor (12). Synthetic prostaglandins have been widely used over the past 20 years in the induction of labor due to their greater efficacy (13,14). Synthetic prostaglandins used in obstetrics are analogues of prostaglandin E2 (Dinoprostone) and analogues of prostaglandin E1 (Misoprostol).

Misoprostol is stable at ambient temperature and can be administered sublingually, buccally, orally or vaginally to induce labor (15). WHO (12) recommends the use of Misoprostol at low

doses and monitoring of the parturient by the cardiotocogram to detect early pathological changes in the fetal heart rate (FHR), hyperkinesia, hypertonia or uterine hyperstimulation which can lead to uterine rupture.

WHO (12) and the International Federation of Gynecologists and Obstetricians (FIGO) (16) recommend doses of 25 micrograms (μg) vaginally every 6 hours or 25 μg orally every 2 hours to induce labor. However, there is no evidence on the optimal number of doses to be administered to increase the rate of vaginal delivery, the same is true for the frequency of doses and the route of administration (17).

Low dose of Misoprostol is well tolerated, but its use after previous cesarean section is associated with a high rate of uterine rupture (18). Misoprostol can be associated with hyperkinesia, hypertonia, uterine hyperstimulation, FHR disorders and this depends on the dose and route of administration, which may be accompanied by an emergency cesarean section then that the latter might not be indicated (19). The Misoprostol available in our environment is 200 μg , hence the difficulty of dividing it by eight in order to obtain the dose of 25 μg as recommended by WHO (12) and FIGO (16), and several structures of health do not have a cardiotocogram for monitoring parturients and fetuses during labor.

This is why we would like to compare the efficacy and safety of the labor induction by 50 μg of oral Misoprostol versus 50 μg in vaginal route in under-equipped health structures, and assess the maternal and perinatal prognosis.

II. PATIENTS AND METHODS

Trial design

It is a single-blind, randomized controlled clinical trial written according CONSORT guidelines. Data collection was prospective from September 1, 2022 to February 01, 2023.

Selection of samples and sampling frame

The study population was pregnant women with full term pregnancy admitted to one of the maternity wards of the selected health structures and having followed the prenatal consultations there. The sample consisted of 177 pregnant women, 89 for oral Misoprostol and 88 for vaginal route. This multi-site study was carried out at the University Clinics of Kisangani, at the Kabondo General Referral Hospital, Alwaleade and Saint-Joseph Referral Health Center, in Kisangani, Tshopo Province, Democratic Republic of Congo (DRC).

Simple size

XLSTAT 2020.3.1.6 was used to calculate the sample size. As this study is a clinical trial comparing the efficacy and safety of misoprostol 50 µg administered by two different routes, we opted for a clinical trial with a non-inferiority test. With a power of 95%, an alpha of 0.05, a standard deviation of 0.5 and a non-inferiority limit of 0.4, the minimum sample size was 134 for both arms, meaning two groups of at least 67 patients

Inclusion criteria

Were included, nulliparous, primiparous and multiparous who controlled their date of last menstruation, and who had a term progressive pregnancy, mono-fetal, with FHR in the standards (110-160 beats per minute), cephalic presentation, without medical or obstetric indication of labor induction and having signed the informed consent.

Exclusion criteria

Were excluded, pregnant women who had already delivery more than five times, twin pregnancy, hypertensive disorders, diabetes, presentation other than cephalic, FHR anomaly before onset, large pregnant uterus, placenta previa, scarred or fibromyomatous uterus, anomalies of the maternal pelvis and cases of fetal death.

This study had the approval of the ethics committee of Kisangani University to and is registered in Panafrican Clinical Trial Registry (PARC) to identification number PACTR202208496861650.

Intervention

Data collection was done during prenatal consultations by trained midwives or nurses, who towards the end of the third trimester informed the pregnant women about the study explaining the advantages and disadvantages of labor induction. At term pregnancy, patients who met the inclusion criteria and signed the informed consent were selected to participate in the study.

In the operational setting, the socioeconomic parameters were evaluated according to the score of Traissac et al (20). Prolonged latency phase was when a dilation of four centimeters could not be achieved eight hours after the onset of uterine contractions.

We induced labor by Miso[®] 200 made by Mylan Laboratories Ltd. Gujarat. India. Lot No 9415A009A (INN: Misoprostol).

After evaluation of the socio-demographic and clinical parameters, 50µg of Misoprostol was administered either orally with a cup of water every six hours until effective uterine contractions were obtained, without exceeding three doses, or by vaginal route following the same frequency and dose. Drug administration was stopped when the parturient reached three uterine contractions per ten minutes or four centimeters cervical dilation. If after three doses the labor did not start, the induction of labor was considered to have failed and the pregnant woman was given an appointment after 24 hours to restart the induction by administering the drug by the same route, same dose and frequency.

Randomization

Recruitment was carried out during antenatal consultations by midwives or nurses who, in the third trimester of pregnancy, scheduled an appointment with the pregnant woman for the day following the probable date of delivery, if labor had not started spontaneously earlier. Patients meeting the inclusion criteria were informed about the study and offered informed consent to participate.

Randomization was carried out using opaque, sealed and numbered envelopes. In other words, when the pregnant woman arrived at the facility, she randomly selected a number from a box containing sealed envelopes, which she handed in to the maternity ward, where she was given a code corresponding to an envelope containing quarters of medication in a plastic case. There was also a note explaining the route of administration (oral or vaginal), the frequency of administration and how to stop or continue taking the drug.

Outcomes

The primary outcomes were the time from drug administrations to uterine contractions, labor time, and vaginal delivery rate. For secondary outcomes, the course of labor as well as the maternal and perinatal prognosis was assessed. Items to assess maternal prognosis were hyperstimulation, uterine pre-rupture or rupture, rate of cesarean sections and delivery hemorrhage. For the perinatal prognosis, FHR disorders were evaluated which was monitored using the Pinard fetoscope, meconium staining of the amniotic fluid, Apgar score at the first, fifth and tenth minutes, need for neonatal care.


Statistical methods

The collected data were encoded on an Excel 2013 sheet and analyzed using SPSS Statistics 20 software. To describe the sample, frequencies, percentages, means and standard deviations were calculated. To measure the significance of proportions, Pearson's Chi2 was calculated, and the difference was considered significant if p-value < 0.05 at the 95% threshold. When the conditions for using Pearson's Chi2 were not applicable, the Fisher exact test was used at the 95% threshold, with significance if the Fisher exact was < 0.05. To measure the strength and direction of association, we calculated the relative risk (RR) with its 95% confidence interval (CI).

For comparisons of means, the t-test was used. The difference was considered significant if p < 0.05 at the 95% threshold.

III. RESULTS

Fig 1. Flow diagram of Schematic representation of women studied



As shown in **Fig.1**, 231 patients were eligible for labor induction. However, 54 were excluded including 16 who had refused to sign the informed consent, and 38 did not meet the inclusion criteria including 8 patients for hypertensive disorders, 6 for scarred uterus, 5 for large pregnant uterus, 12 patients who already had delivered more than 5 times, and 7 for surgical pelvis. We selected 177 patients who met the criteria and who agreed to participate in the study, including 89 for oral Misoprostol and 88 for the vaginal route.

Table 1: Patients Details

IV.	Oral (n=89)	Misoprostol	Vaginal (n=88)	Misoprostol	<i>p</i> -value
<i>Age (years)</i> means ± SD	23.73±6.29		25.62±7.24		0.23
18-19	28 (31.5)		30 (34.1%)		
20-34	51 (57.3%)		41 (46.6%)		
≥ 35	10 (11.2%)		17 (19.3%)		
<i>Marital Status</i>					0.34
Married	72 (80,9%)		69 (78.4%)		
Single	17 (19,1%)		19 (21.6%)		
<i>Profession</i>					0.84
Pupil/Student	26 (29.2%)		27 (30.7%)		
Without	43 (48.3%)		38 (43.2%)		
Salaried	8 (8.9%)		10 (11.4%)		
Informal sector	12 (13.6%)		13(14.7%)		
<i>Socio-economic level</i>					0.83
Low	45 (50.6%)		47 (53.4%)		
Medium	40 (44.9%)		36 (40.9%)		
High	4 (4.5%)		5 (5.7%)		
<i>Education level</i>					0.52
Illiterate	5 (5.6%)		4 (4.5%)		
Primary	27 (30.3%)		22 (25.0%)		
Secondary	45 (50.6%)		43 (48.9%)		
Superior	12 (13.5%)		19 (21.6%)		

As shown in **Table 1**, the majority of the patients were married, aged 20-34 years, with a average of 23.73±6.29 years for oral group vs 25.62±7.24 for vaginal group, without profession 43 (48.3%) vs 38 (43.2%), of low socioeconomic level 45 (50.6%) vs 47 (53.4%) and of secondary education level 45 (50.6%) vs 43 (48.9%). The two groups are comparable because there was no significant difference from these parameters.

Table 2. Gyneco-obstetrical parameters of patients

Parameters, means \pm SD	Oral Misoprostol	Vaginal Misoprostol	<i>p</i> -value
Parity	0.73 \pm 1.12	1.11 \pm 1.29	0.07
Nulliparous	61 (68,5%)	49 (55,7%)	
Primiparous	19 (21,4)	19 (21,6%)	
Multiparous	9 (10,1)	20 (22,7%)	
BMI (Kg/m²)	25.62 \pm 2.81	26.45 \pm 3.59	0.13
< 25	53 (59.6)	45 (51.1%)	
\geq 25	36 (40.4)	43 (48.9%)	

As shown in **Table 2**, the majority of patients was nulliparous, and had a BMI < 25 kg / m. The difference was not significant statistically in the two groups.

Table 3. Comparison of the efficacy of misoprostol of patients

Parameters	Oral Misoprostol	Vaginal Misoprostol	Relative Risk (RR) 95% CI	<i>p</i> -value
Primary results				
Induction-uterine contractions (hrs) : means \pm SD	6.18 \pm 4.11	4.03 \pm 1.99	-	
\leq 12 hrs	81 (91.1%)	88 (100.0%)		0.00*
> 12 hrs	8 (8.9%)	0 (0.0%)		
Duration of labor (hrs) except in case of cesarean section	10.85 \pm 3.59	9.39 \pm 2.55	-	
\leq 8 hrs	21/83 (25.3%)	26/77 (33.8%)		0.29
9-16 hrs	52/83 (66.7%)	50/77 (64.9%)		0.44
>16 hrs	10/83 (12.1%)	1/77 (1.3%)		0.01*
Induction-delivery delay (hrs)	16,88 \pm 6,11	13,03 \pm 3,32		
\leq 12 hrs	28 (31.5%)	44 (61.1%)	1.49 [1.07-2.08]	0.01*
\leq 24 hrs	79 (88.8%)	87 (98,9%)	1.91 [1.49-2.44]	0.00*
> 24 hrs	10 (11.2%)	1 (1.1%)	0.52 [0.41-0.67]	0.00*

<i>Number of doses at delivery</i>				
Delivery at dose 1	26 (29.2%)	42 (47.7%)	1.51 [1.07-2.13]	0.01*
Delivery at dose 2	47 (52.8%)	43 (48.9%)	0.92 [0.69-1.24]	0.30
Delivery at dose 3	13 (14.6%)	2 (2.3%)	0.54 [0.42-0.70]	0.01*
Delivery after 3 doses	3 (3.4%)	1 (1.1%)	0.66 [0.37-1.19]	0.19
<i>Side effects</i>				
Chills	3 (3.4%)	0 (0%)	0.49 [0.43-0.57]	0.06
Diarrhea	1 (1.1%)	0 (0%)	0.50 [0.43-0.58]	0.25

*Significant difference

As shown in **Table 3**, uterine contractions occurred on average after 6.18 ± 4.11 hrs in oral group versus 4.03 ± 1.99 hrs in vaginal group and the difference was significant ($p=0.00$). The delivery rate beyond sixteen hrs was 12.1% (10 patients) for the oral route and the difference was significant ($p=0.01$) compared to the vaginal route 1.3% (1 patient). Vaginal Misoprostol caused more delivery within twelve to twenty-four hrs and the difference was significant compared to the oral route ($p=0.01$ and $p=0.00$ respectively).

Oral misoprostol resulted in 10 (11.2%) delivery after 24 hrs, and the difference was significant ($p=0.00$) compared to vaginal route 1 (1.1%). After the first dose, 42 (47.7%) patients delivered for vaginal Misoprostol versus 26 (29.2%) for the oral route and the difference was significant ($p=0.01$), RR 1.5, 95% CI 1.07-2.13. The majority of patients who reached the third dose received oral Misoprostol 13 (14.6%) versus 2 (2.3%) vaginally and the difference was significant ($p=0.01$).

Table 4. Comparison to the course of labor and maternal prognosis

Parameters	Oral Misoprostol	Vaginal Misoprostol	RR 95% CI	<i>p</i> -value
Secondary results				
Number of doses				
Means \pm SD	97.19 \pm 41.54 μ g	76.71 \pm 27.28 μ g		
≤ 3	86 (96,6%)	87 (98,9%)	1,51 [0,84-2,71]	0,19
> 3	3 (3,4%)	1 (1,1%)		
Failure induction	3 (3.4%)	0 (0.0%)	0.49 [0.43-	0.06

			0.57]	
Prolonged latency phase (> 8hrs)	12 (13.6%)	0 (0.0%)	0.47 [0.39- 0.55]	0.00*
Hyperstimulation	4 (4.5%)	7 (7.9%)	1.41 [0.64- 3.12]	0.18
Delivery route			1.5 [0.76-2.85]	0.10
Vaginal delivery	83 (93.3%)	77 (87.5%)		
Cesarean section	6 (6.7%)	11 (12.5%)		

* Significant difference

As shown in **Table 4**, the prolonged latency phase had occurred in 12 (13.6%) of patients in oral group and the difference was significant ($p = 0.00$) compared to the vaginal group where no case had been recorded. The rate of uterine hyperstimulation was 7.9% in vaginal group versus 4.5% in oral group, RR 1.41, 95% CI 0.64-3.32.

The majority of patients delivered vaginally, including 83 (93.3%) for the oral route versus 77 (87.5%) for the vaginal route. However, the cesarean section rate was 11 (12.5%) for the vaginal route versus 6 (6.7%) for the oral route, RR 1.5, 95% IC 0.76-2.85.

Table 5. Comparison to perinatal prognosis

Parameters	Oral Misoprostol	Vaginal Misoprostol	RR 95% CI	<i>p</i> -value
Secondary results				
FHR disorders	5 (5.6%)	8 (9.1%)	1.33 [0.65-2.69]	0.19
Meconium staining of amniotic fluid	6 (6.7%)	15 (17.1%)	1.86 [0.93-3.72]	0.02*
Apgar Score				
Apgar < 7 1 st minute	8 (8.9%)	13 (14.8%)	1.36 [0.77-2.40]	0.92
Apgar < 7 5 th minute	0 (0)	0 (0)	-	-
Neonatal care	4 (4.5%)	8 (9.1%)	0.65 [0.29-1.46]	0.12
Stillbirth	0 (0)	0 (0)	-	-

* Significant difference

As shown in **Table 5**, by the vaginal route, the rate of meconium staining of the amniotic fluid was 17.1% (15) for vaginal Misoprostol versus 6.7% (6) for the oral route, RR. 1.86, 95% IC 0.93-3.72, and the difference was significant ($p = 0.02$). The low Apgar level at the first minute was 14.8% (13) for the vaginal route versus 8.9% (8) for the oral route, RR 1.36, 95% CI 0.77-2.40.

V. DISCUSSION

4.1. Misoprostol administration and time to uterine contractions

Uterine contractions occurred on average after 6.18 ± 4.11 h for oral Misoprostol versus 4.03 ± 1.99 h for the vaginal route. The rate of occurrence of uterine contractions during the first three doses, which corresponds to 12 hours from the start of Misoprostol administration, was 91.1% for the oral route versus 100% for the vaginal route, ($p=0.00$). This reflects that vaginally Misoprostol triggered uterine contractions faster than orally. This is consistent with the results of a study who compared $25\mu\text{g}$ Misoprostol vaginally versus $50\mu\text{g}$ orally which he administered every six hours found that the duration of onset of uterine contractions was prolonged for the oral route ($7.5 \pm 4.4\text{h}$) versus 6.6 ± 3.6 for the vaginal route ($p=0.1$) (21). However, in another study, authors administered $50\mu\text{g}$ Misoprostol every 4 hours and found a delay in onset of uterine contractions of $4.2 \pm 0.66\text{h}$ for the oral route versus $5.06 \pm 1.1\text{h}$ for the vaginal route (22). These results are thought to be due to a shorter interval between doses (4h) because vaginally Misoprostol has a slow absorption and a lower peak plasma level than oral administration (23). Thus, with oral administration, and at closer intervals, Misoprostol can stimulate uterine contractions earlier than when administered vaginally.

4.2. Misoprostol Administration and Duration of Labor

The mean duration of labour excluding caesarean section was 10.85 ± 3.59 h for oral Misoprostol versus 9.39 ± 2.55 h for the vaginal route. However, with oral Misoprostol, 12.1% of patients had a labour duration >16 hours vs. 1.3% with vaginal Misoprostol ($p=0.01$). These data are almost similar to those found in a study which were $8.4 \pm 0.92\text{h}$ for the oral route vs $9.2 \pm 1.5\text{h}$ for the vaginal route (22). In another study, authors compared $25\mu\text{g}$ Misoprostol vaginally every 2h vs $50\mu\text{g}$ peros every 6h and found a mean duration of 31h vs 41h respectively (24). Hence, the duration of labour would be shorter when Misoprostol is administered vaginally. However, a study found a mean duration of 21.02 ± 16.9 h for the oral

route vs 23.95 ± 54.28 for the vaginal route ($p=0.47$) (25). The duration of labour was longer for the vaginal route in this study because they started with $25\mu\text{g}$ Misoprostol for the first intra vaginal dose and increased the dose to $50\mu\text{g}$ if uterine contractions were not effective whereas with the oral route they started directly with $50\mu\text{g}$. However, another study found that the duration of induction of labour in the active phase was shorter for vaginal than for oral Misoprostol and the difference was significant (26).

The majority of pregnant women delivered within 24 hours of induction of labour, 88.8% for the oral route versus 98.9% for the vaginal route ($p=0.00$). A study found a 24 hours delivery rate of 44.9% for the oral route vs 53.5% for the vaginal route ($p=0.27$) (25). This reflects that the $50\mu\text{g}$ Misoprostol every 6 hours protocol is effective both orally and vaginally, but the vaginal route is statistically more effective. However, another study found a 24-hour delivery rate of 88.2% for the oral route vs. 85.7% for the vaginal route when inducing labour with $25\mu\text{g}$ Misoprostol peros every 2 hours vs. $25\mu\text{g}$ vaginally every 6 hours with a maximum duration of 24 hours (27). This high rate of delivery within 24 hours for oral Misoprostol is thought to be related to the shorter dosing interval for this route.

The mean interval between the first dose and delivery was longer (16.88 ± 6.11 h) for oral misoprostol versus 13.03 ± 3.32 h for the vaginal route. A study found an interval of 16.47h (4-28h) for the oral route vs 6h (3.24-26.32h) for the vaginal route and the difference was significant ($p=0.0033$) (15). Vaginally administered Misoprostol is fast acting as it is close to the body and cervix, but is slowly eliminated from the maternal body hence its bioavailability is longer compared to oral administration where it has to be absorbed from the gastrointestinal tract, undergo the first hepatic pass where it is catabolised, binds to plasma proteins and only its free form will be active (Misoprostol acid) (23). However, another study administered $50\mu\text{g}$ every 6h for the oral route vs $25\mu\text{g}$ every 6h for the vaginal route and found a shorter interval for the oral route (22.6 ± 17.22 h) vs 25.5 ± 54.25 h for the vaginal route but the difference was not significant ($p=0.47$) (25). Similarly, a study found an interval of 18.48 ± 2.01 h for the oral route vs 22.82 ± 2.50 h for the vaginal route ($p=0.00$) (27). This proves that Misoprostol administered at shorter intervals by the oral route would be more effective than by the vaginal route.

Vaginal Misoprostol resulted in more deliveries within twelve to twenty-four hours and the difference was significant compared to the oral route ($p=0.01$ and $p=0.00$ respectively). In a study also found that vaginally administered Misoprostol resulted in more deliveries within 24 hours (90.4%) versus 72.5% when administered orally (26). Another study found a delivery

rate of 13.8% for the oral route vs. 17.4% for the vaginal route within 12 hours ($p=0.64$), and 44.9% for the oral route vs. 53.5% for the vaginal route within 24 hours ($p=0.27$) (25). Hence, vaginal Misoprostol is more effective and results in a higher rate of delivery within 24 hours than the oral route.

Oral Misoprostol resulted in 10 (11.2%) deliveries after 24 hours, and the difference was significant ($p=0.00$) compared to the vaginal route 1 (1.1%). A study found a delivery rate within 48 hours of 64.1% for the oral route vs 66.9% for the vaginal route and the difference was not significant (25). This would be related to the low doses ($25\mu\text{g}$) of vaginal Misoprostol with which they started the induction and only administered $50\mu\text{g}$ in the absence of effective uterine contractions, hence the number of doses was increased and the duration of labour prolonged. Another study conducted in nulliparous women and gave one group $50\mu\text{g}$ of Misoprostol orally every 4 hours up to 3 doses and the other group $200\mu\text{g}$ of Misoprostol in the posterior vaginal fornix which was removed after at least 3 uterine contractions or 4 cm cervical dilatation, and found a 24-hour delivery rate of 44.1% for the vaginal route vs. 14.1% for the oral route ($p=0.001$) (28). Hence, continuous administration of Misoprostol by the vaginal route improves its effectiveness.

4.3 Adverse events in relation to the routes of administration of Misoprostol

Adverse events were only noted with oral administration of Misoprostol, including: chills 3 (3.4%) and diarrhoea 1 (1.1%). A study found a rate of nausea of 10.9% for the oral route versus 0% for the vaginal route, RR 27.07 at 95% CI, 1.17-465.7 (29). Similarly, another study found a diarrhoea rate of 1.7% for vaginal Misoprostol vs. 0% for oral ($p=0.16$), nausea rate of 9.3% for vaginal vs. 9.6% for oral ($p=0.73$) and a vomiting rate of 14.0% for vaginal vs. 17.4% for oral ($p=0.18$) (25). This suggests that the oral route would have more side effects on the gastrointestinal tract than the vaginal route, however the difference is not significant compared to the oral route. The low rate of adverse events is thought to be related to the low dose of Misoprostol ($50\mu\text{g}$) administered in our study which is extremely lower than the optimal dose in terms of occurrence of side effects ($400\mu\text{g}$) (30).

4.4. Number of doses of Misoprostol administered

Administered orally, 86 (96.6%) patients received a maximum of 3 doses versus 87 (98.9%) for the vaginal route ($p=0.19$), RR 1.51, 95% CI 0.84-2.71. Similarly, in a study, authors used the protocol of $50\mu\text{g}$ Misoprostol taken every 4 hours up to a maximum of 6 doses and found that 85% of patients received a maximum of 3 doses for the oral route versus 84% for the

vaginal route and the difference was not significant (31). In another study author found a rate of 5.88% of patients who received a single dose of Misoprostol orally vs. 11.54% vaginally, 15.69% for 3 doses orally vs. 19.23% vaginally, but 11.77% for six doses orally vs. 5.77% vaginally (15). This reflects that the number of doses administered was lower when inducing labour with Misoprostol vaginally compared to orally.

The average dose of Misoprostol by the oral route was $97.19 \pm 41 \mu\text{g}$ versus $76.71, \pm 27.28 \mu\text{g}$ by the vaginal route. In a study, authors induced labour with $50 \mu\text{g}$ of Misoprostol every 4 hours and found a mean administered tablet of 2.5 ± 1.3 for the oral route versus 2.0 ± 1.1 for the vaginal route ($p=0.02$) (32). Misoprostol administered vaginally would be associated with a reduction in the number of doses compared to the oral route. In another study authors found a mean dose of $257 \mu\text{g} \pm 144 \mu\text{g}$ (28). These high doses would be related to the fact that on the first day they administered $50 \mu\text{g}$ every 4 h up to a maximum of 3 doses. However, in case of failure, the next day they administered $100 \mu\text{g}$ of Misoprostol every 4 hours without exceeding $300 \mu\text{g}$. It is recommended not to exceed $150 \mu\text{g}$ of Misoprostol per 24 hours when inducing labour in a full term pregnancy due to possible maternal and perinatal complications (1,23).

4.5. Failure rate of induction and prolonged latency phase in relation to the route of administration of Misoprostol

The failure rate was 3.4% (3 patients) and this was only found with oral Misoprostol induction of labor. In a study authors found a failure rate of 4.3% for the vaginal route vs. 11% for the oral route (95% RR CI 0.39[0.15-1.02]) (33). In another study, authors administered $50 \mu\text{g}$ Misoprostol every 4 hours with a maximum of six doses and found a failure rate of 25.49% for the oral route vs 9.62% for the vaginal route and the difference was significant ($p=0.0426$) (15). This indicates that there is a higher risk of failure when inducing labor with oral Misoprostol. However, in another study found a failure rate of 5% for the oral route versus 6% for the vaginal route and this would be related to the close interval of $50 \mu\text{g}$ of Misoprostol every 4 hours for both routes which may potentiate the efficacy of the oral route (22).

Prolonged latency occurred in 12 (13.6%) patients when inducing labor with oral Misoprostol and the difference was significant ($p=0.00$) compared to the vaginal route where no cases were recorded. This is related to the protocol of $50 \mu\text{g}$ of Misoprostol orally every six hours as its absorption and elimination is rapid by this route compared to the vaginal route (26,33). Thus, WHO (12) and FIGO (16) recommend doses of $25 \mu\text{g}$ Misoprostol orally every two

hours versus 25µg vaginally every six hours until effective uterine contractions are achieved. In a study authors found a time interval from induction to onset of active phase of 6 hours for vaginal Misoprostol versus 9.25 hours for oral Misoprostol and the difference was significant ($p=0.0049$) (15). However, in another study authors inducing labor with 100µg Misoprostol to be taken every 4 hours for the oral route versus every 6 hours for the vaginal route found a mean duration of 7.5 ± 4.2 hours for the oral route versus 7.3 ± 4.1 for the vaginal route and the difference was not significant ($p=0.87$) (34). Hence, Misoprostol per os administered at 100µg would reduce the rate of prolonged latency phase.

4.6. Maternal prognosis in relation to the route of administration of Misoprostol

The rate of uterine hyperstimulation was 4.5% for the oral route versus 7.9% for the vaginal route, RR 1.41 at 95% CI 0.64-3.12, but the difference was not significant ($p=0.18$). In a study, authors found a uterine hyperstimulation rate of 2% for the oral route versus 14% for the vaginal route. A study (15) used the protocol of 50µg Misoprostol administered every four hours up to a maximum of six doses and found no cases of hyperstimulation or uterine rupture compared to both groups. In another study, the rate of uterine hyperstimulation were 4.8% for the oral route versus 9.4% for the vaginal route but the difference was not significant ($p=0.27$) (25). However, a study found a uterine hyperstimulation rate of 9% for oral Misoprostol versus 5% for the vaginal route (31). This rate is thought to be related to the 4-hour interval between doses of 50µg Misoprostol, which potentiates the efficacy of oral Misoprostol, but also its adverse effects.

In our study, we did not have any cases of uterine rupture. Several other studies that used the maximum dose of 50µg Misoprostol did not find any cases of uterine rupture (15,25,33). This indicates that the 50µg dose of Misoprostol is well tolerated by parturients. However a study (26) compared the two routes using a protocol of 50µg every 4 hours until effective uterine contractions were achieved and found a 0.5% rate of uterine rupture that occurred in a patient with a scarred uterus and induction was done with Misoprostol vaginally. This suggests that induction of labor with per os Misoprostol would be safer than vaginal induction.

4.7. Route of delivery after induction of labor with Misoprostol

The rate of vaginal delivery was 83 (93.3%) when Misoprostol was administered orally versus 77 (87.5%) for the vaginal route and the difference was not significant ($p=0.10$). A study (26) found a vaginal delivery rate of 74% for the oral route versus 94% for the vaginal route. They induced labor in patients with medical indications for induction including gestational

hypertension, IUGR, gestational diabetes and oligohydramnios. And another study (15) found a vaginal delivery rate of 74.5% for the oral route versus 90.4% for the vaginal route and the difference was significant ($p=0.0462$). This indicates that by inducing labor with Misoprostol in the same doses, the vaginal route offers a better chance of achieving vaginal delivery regardless of the indication. In our study we obtained a higher rate of vaginal delivery for the oral route than for the vaginal route because at the same dose and frequency, vaginal Misoprostol increases the risk of caesarean delivery more than oral Misoprostol.

In our study, the caesarean section rate was 6.7% for the oral route versus 12.5% for the vaginal route, RR 1.5 at 95% CI 0.76-2.85 for vaginal Misoprostol but $p=0.10$. A study (33) found a caesarean section rate of 30.2% for the oral route versus 31.9% for the vaginal route (RR 1.06, 95% CI 0.7-1.5). Another study (25) found a caesarean rate of 32.9% for the oral route versus 31.4% for the vaginal route ($p=0.21$). This high caesarean rate in this studies was related to the body mass index of the patients which was on average 33.54 kg/m². In both groups reflects that a BMI ≥ 25 kg/m² is associated with prolonged duration of labor which may indicate a caesarean section (35).

4.8. Perinatal prognosis in relation to route of administration

The rate of pathological changes in BCF (fetal heart sounds) was 5.6% for the oral route versus 9.1% for the vaginal route, RR 1.33 at 95% CI 0.65-2.69. A study (25) found that neonatal acidemia (umbilical artery pH < 7.0) was common with vaginal Misoprostol reflecting hypoxia, and the difference was significant ($p=0.04$) compared to the oral route. Hence, the vaginal route would increase the risk of occurrence of fetal distress. However, another study (26) found a rate of 20% of pathological changes in the FHR for the oral route versus 10% for the vaginal route. These high rates are thought to be related to the fact that they induce labour in medically indicated patients whose hypertensive disorders had a rate of 84% for the oral route versus 86% for the vaginal route.

The rate of meconium staining of the amniotic fluid (AF) was 6.7% for the oral route versus 17.1% for the vaginal route, RR 1.86 at 95% CI (0.93-3.72) ($p=0.02$). A study (28) also found a meconium staining rate of 33.8% for the vaginal route versus 18.5% for the oral route, RR 2.38, 95% CI 1.32-4.29 ($p=0.004$). This further reflects that the risk of fetal distress is higher when inducing labour with Misoprostol vaginally. However, another study (15) monitoring partients by cardiotocography, found a rate of meconium staining of the LA of 1/51 for the oral route vs 1/52 for the vaginal route ($p=0.899$). These almost similar rates would be related

to the electronic monitoring of the parturient that detects early signs of fetal distress that indicated caesarean sections at a rate of 25.5% for oral Misoprostol versus 9.6% for vaginal Misoprostol ($p=0.0462$).

The Apgar score < 7 at the first minute was 8 (8.9%) for oral versus 13 (14.8%) for vaginal, RR 1.36 at 95% CI 0.77-2.40 ($p=0.92$). Note that at five minutes postpartum, the Apgar score was ≥ 7 for both routes. A study [27] also found an Apgar rate <7 at 5 minutes of 1.2% for the oral route versus 2.4% for the vaginal route, RR 0.49, 95% CI 0.05-6.65. Another study (25) found an Apgar rate <7 at the first minute of 16.2% for the oral route vs 21.5% for the vaginal route ($p=0.16$). At five minutes, they found an Apgar < 4 of 1.2% and 2.7% pH < 7.0 at the umbilical artery only for the vaginal route; and Apgar < 7 of 2.4% for the oral route vs. 1.7% for the vaginal route with $p=0.69$. This would suggest that the risk of low Apgar at 5 minutes is more related to induction of labor with vaginal Misoprostol.

The rate of neonatal management was higher with vaginal Misoprostol induction 9.1% vs. 4.5% for oral induction ($p=0.12$). A study (28) found a neonatal management rate of 3.0% for oral versus 4.5% for vaginal induction and $p=0.83$. Another study (33) who only induced labor in nulliparous women, found a neonatal management rate of 9.3% for the oral route vs 11.2% for the vaginal route with RR 1.2 at 95% CI 0.60-2.4. Hence the risk of neonatal resuscitation is higher when inducing labor with vaginal Misoprostol compared to the oral route.

V. CONCLUSION

Labor induction with misoprostol is effective both orally and vaginally. Its use at low doses in under-equipped settings may be recommended due to its ease of storage and administration and the wide range of routes of administration. Misoprostol administered vaginally is more effective because it reduces the time to onset of uterine contractions and the duration of labor. Orally, Misoprostol improves maternal and perinatal prognosis by reducing the risk of complications.

CONTRIBUTION OF THE AUTHORS

Dr Matega designed the project, established the standard protocol, collected the data and wrote the manuscript. Dr Matega and Dr Maindo had encoded and analyzed the results. Dr Maindo, Dr Bosenge, Dr Labama, Professors Juakali, Modia, Manga and Katenga had critically reviewed the content and validated the final version of the manuscript.

Ethical Approval and Consent: The study was prospective, had the approval of the ethics committee of Kisangani University, and Patients signed the informed consent.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc. have been used during the writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

REFERENCES

1. Esayu T., Bezalem E. 2018. Success of labour induction institution based cross-sectional Study Wolaita Sodo, South Ethiopia. *International Journal of Nursing and Midwifery*; 10(12):161-167
2. Abdoukibir Y., Geremew M, Dechasa B. 2017. Induction of Labor Prevalence and Associated Factors for its Outcome at Walliso St. Luke, Catholic Hospital, South West Shewa Oromia. *International Medecine Open Access Journal*. 7:255
3. Dean L., Anne B., Lily L., Jessica D. 2016. Déclenchement du Travail. *J Obstet Gynaecol*; 38(12S) : S 287-S310
4. WHO 2005: Systematic review of maternal mortality and morbidity : the prevalence of uterine rupture. *BJOG*, Vol 112, pp. 1221-1228
5. WHO 2010. Global Survery on Maternal and Perinatal Health. Geneva, World Health Organization.

6. Little S. 2017. Elective induction of labor : what is the impact ? *Obstetrics and Gynecology Clinics of North America*; 44(4):601-614
7. Mbele A, Makin J, Pattinson R. 2007. Can the outcome of induction of labor with oral misoprostol be predicted? *Org Art*; 97 : 289-292
8. Oshodi Y., Agbara J., Fabamwo A., Oyedele Y., Akinlufu F., Ottun T. 2017. Feto-maternal outcome of induced versus spontaneous labour in Nigerian Tertiary Maternity Unit. *Trop J Obstet Gynaecol*; 34 : 21-7
9. Matega H, Maindo A, Bosenge N., Wembakoy O., Labama O., Juakali S., Modia O., Manga O., Katenga B. 2021. Prévalence et pronostic du déclenchement artificiel du travail d'accouchement à Kisangani, RD Congo. *Kisangani Médical*. 11(1):458-466
10. Labama L. 2011. *Obstétrique du praticien*. Kisangani, Pbl Presses de l'Université de Kisangani. 507 pages
11. Rydahl E., Ericksen L., Juhl M. 2019. Effects of induction of labor prior to postterm in low-risk pregnancies : a systematic review. *JBI Database System Rev Implement Rep*; 17:170-208
12. WHO2011. *Recommandations for induction of labour*. World Health Organization Geneva,
13. Hossam S., Ismail M., Ashraf H. 2018. Comparative Study Between Sublingual and Vaginal Misoprostol for Induction of Labor in Post Term Patients with Unfavourable Cervix. *The Egyptian Journal of Hospital Medicine*. Vol. 72 (6), Page 4707-4711
14. Ambreen A., Waseem T., Nabecla S., Shaila A. 2011. Induction of labor. A comparison between Misoprostol and Dinoprostol. *PJMHS* Vol.5 N°4. 620
15. Jindal P., Avatshi K., Kaur M. 2011. A comparative of vaginal versus oral misoprostol for induction of labor. Double Blinding Randomized Trial. *The Journal of Obstetrics and Gynecology of India*; 61(5) : 538-542
16. FIGO2017. Misoprostol-only. Recommended regimes. Online www.figo.org
17. Veronica M., Moona A., Jee-Young M., Alexander W., Arisa K., Peter S., Pamela J. 2018. Induction of labor using one dose vs multiple doses of misoprostol: A Randomized Controlled Trial. *Am J Obstet Gynecol*; 218(6):614.e1-614.e8

18. Rath W., Tsikouras P. 2015. Misoprostol for Labour Induction after Previous Cesarean Section – Forever a “No Go”? *Geburtshilfe Frauenheilkd.*; 75(11):1140-1147
19. Vogel J., West H., Dowswell T. 2013. Titrated oral misoprostol for augmenting labour to improve maternal and neonatal outcomes. *Cochrane Database Syst Rev.* 23 ; (9) : CD010648
20. Traissac P., Delpeuch F., Maire B., Martin Prevel Y., Cornu A., Trèche S. 1997. Construction d'un indice synthétique de niveau socio-économique des ménages dans les enquêtes nutritionnelles-Exemple d'application au Congo. *Rev. Epidemiol. Santé Publique* ; 45 (S1) : 114-115
21. Rezaie M, Farhadifar F, Sadegh S, Nayebi M. 2016. Comparison of vaginal and oral doses of Misoprostol for labour induction in post-term pregnancies. *J Clin Diagn Res*;10(3):08-11
22. Dadashaliha M., Fallah S., Mirzadeh M. 2021. Labor induction with randomized comparison of cervical, oral and intravaginal Misoprostol. *BMC Pregnancy Childbirth*;21(1):721
23. Rebecca A., Barbara O. 2009. Use of Misoprostol in obstetrics and gynecology. *Rev Obstet Gynecol* ; 2(3):159-168
24. Handal-Orefice R., Friedman A., Chouinard S., Eke A., Feinberg B., Politch J., Iverson R., Yarrington C. 2019. Oral or Vaginal Misoprostol for Labor Induction and Cesarean Delivery Risk. *Obstet Gynecol* ;134(1):10-16
25. Young D., Delaney T., Armson B., Fanning C. 2020. Oral misoprostol, low dose vaginal misoprostol, and vaginal dinoprostone for labor induction: Randomized controlled trial. *PLOS ONE* January. <https://doi.org/10.1371/journal.pone.0227245>
26. Kirian S. 2018. Comparison of Vaginal vs Oral Misoprostol for induction of Labor at Term Gestation. *Scholars Journal of Applied Medical Sciences*; 6(12): 4643-4646. Available online : <http://saspublisher.com/sjams/>
27. Hauwa U., Shittu S. Umar-Sulayman H., Audu B. 2019. A comparison of oral versus vaginal misoprostol for induction of labor at term, at the Ahmadu Bello University Teaching Hospital, Zaria. *Trop J Obstet Gynecol* ;36:189-95

28. Hokkila E., Kruit H., Rahkonen L., Timonen S., Mattila M., Laatio L., Ordén M., Uotila J., Luukkaala T., Tihtonen K. 2019. The efficacy of misoprostol vaginal insert compared with oral misoprostol in the induction of labor of nulliparous women: A randomized national multicenter trial. *Acta Obstet Gynecol Scand*; 98:1032-1039
29. Cheng S, Ming H, Lee J. 2008. Titrated Oral compared with vaginal Misoprostol for labor induction: a randomized controlled trial. *Obstetrics and Gynecology*; 111(1):119-125
30. Singh K., Fong Y. 2000. Preparation of the cervix for surgical termination of pregnancy in the first trimester. *Hum Reprod Update* ; 6:442-448.
31. Ayaz A, Saïd S, Farooq U, Ahmad I, Bahoo M, Saïd M. 2009. Labour induction with randomized comparison of oral and vaginal Misoprostol in postdate multigravida women. *Malays J Med Sci* ; 16(1):34-8
32. Ezechukwu P., Onyebuchi U., Nnambi O., Chibuïke O. 2015. Oral Versus Vaginal Misoprostol for Induction of Labor in Enugu, Nigeria : A Randomized Controlled Trial. *Arch Gynecol Obstet* ; 291(3):537-44
33. Axelina E., Sarah J., Lone K. 2020. Induction of labor in nulliparous women-quick or slow: a cohort study comparing slow-release vaginal insert with low-dose misoprostol oral tablets. *BMC Pregnancy and Childbirth* ; 20:79
34. Zoqeen A. 2010. Comparison of oral versus vaginal Misoprostol for induction of labor at term. *Journal of Rawalpindi Medical College*; 14(2):104-106
35. Matega H, Maindo A., Bosenge N., Wembakoy O., Labama O., Juakali S., Modia O., Manga O., and Katenga B. 2021. Labor Induction with Oral Misoprostol in Term Pregnancy: A Clinical Trial. *Journal of Biosciences and Medecine* ; 9:74-88
<https://doi.org/10.4236/jbm.2021.910007>